ETS1 and nonpapillary renal cell carcinoma: Interestingly, we found that knocking down NEK1 or treating ccRCC cells with the NEK1 inhibitor increased the acetylation level of ETS1‐K245, but overexpressing NEK1 WT decreased the level of ETS1‐K245ac (Figure 6H).